Nexeon MedSystems Inc. (“Nexeon” or “the Company”) announced today that it has closed a round of private funding that included new and previous investors. This round will allow the Company to expand manufacturing capacity to service additional customers and to begin building commercial product launch infrastructure in Europe.
En 2013, le président Obama a lancé la BRAIN Initiative,un effort de grande envergure pour munir les chercheurs du savoir nécessaire pour traiter une grande variété de troubles cérébraux comme l'Alzheimer, la schizophrénie, l'autisme, l'épilepsie et le traumatisme crânien. L'Organisation mondiale de la santé estime que des troubles cérébraux dévastateurs touchent plus d'un million de personnes mondialement.
Nexeon Medsystems, Inc. verwerft, via een volle dochter, de controle over Rosellini Scientific Benelux B.V.B.A. (RSB, Seraing). Rosellini Scientific Benelux, dat ook een vestiging in het Wetenschapspark te Niel heeft, wordt tot Nexeon Medsystems Belgium B.V.B.A. herdoopt. RSB nam eerder Synaptix B.V.B.A. (Niel) uit curatèle over. Synaptix ontwikkelde een tool met CE-keurmerk voor het stimuleren van diepe hersenactiviteit. Het bedrijf beschikte tevens over geavanceerde expertise voor de ontwikkeling en fabricatie van medische instrumenten. Bedoeling van Nexeon is de productie- en IP-licentiëring activiteiten in België verder te zetten.
Lexington, KY – Nexeon Medsystems, Inc. (“Nexeon” or “the Company”) will present the findings of two preclinical programs that are exploring additional applications of neurostimulation: dysphagia and overactive bladder (OAB). These studies were funded by Small Business Innovative Research (SBIR) grants based on ingenuity in addressing present-day clinical unmet needs. Dr. Navid Khodaparast will represent the Company as the contributing research scientist for both programs.
Will Rosellini was once a minor league baseball player. But he found he couldn’t do what other pitchers could do. He retired and began searching for answers. It had to do with his nervous system, and that set him on a 15-year journey to marry neuroscience and technology.
La compañía bioelectrónica Nexeon MedSystems ha cerrado un acuerdo para adquirir Rosellini Scientific, que también es una epresa bioelectrónica. Nexeon pretende aumentar sus capacidades de fabricación y de propiedad intelectual con esta compra, al igual que incrementar las operaciones de concesión de licencias en Bélgica.
eNewsChannels NEWS: SAN FRANCISCO, Calif. — Several promising neurotechnology firms and key industry figures will present at the 2016 Neurotech Leaders Forum. The 16th annual event will take place October 24-25 in San Francisco, presented by Neurotech Reports. Keynote speaker at this year’s event on October 24 will be Doug Weber, who serves as program manager for DARPA’s Biological Technologies Office. Prior to joining DARPA, Weber was an associate professor of bioengineering at the University of Pittsburgh. He received his Ph.D. in bioengineering at Arizona State University.
William Rosellini was a minor league pitcher in the Arizona Diamondbacks organization for about a year. His professional baseball career had one insurmountable flaw: he couldn’t throw his curveball consistently for strikes. Still, 15 years later, the experience still informs his work.
I recently had the pleasure to speak with Eidos Montreal’s primary bionics consultant for the Deus Ex series, Will Rosellini. Will has been involved with the franchise since the development of Deus Ex: Human Revolution and has had a major influence on the developer’s depiction of future human augmentation. It was a fascinating conversation, and likely not our last: Will is pushing a lot of new technology, both in and outside the world of Deus Ex.